Selecta Biosciences (SELB) Misses Q3 EPS by 9c; Reports Cash and Cash Equivalents of $140.0M

Selecta Biosciences (NASDAQ: SELB) reported Q3 EPS of ($0.16), $0.09 worse than the analyst estimate of ($0.07). Revenue for the quarter came in at $24.4 million versus the consensus estimate of $12.19 million.

For earnings history and earnings-related data on Selecta Biosciences (SELB) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Traws Pharma (TRAW) Tops Q2 EPS by 27c
• Phillip Securities Reiterates Buy Rating on Sea Ltd. (SE)